Incyte (Nasdaq: INCY) has announced its participation in the 2025 American Academy of Dermatology (AAD) Annual Meeting, scheduled for March 7–11, 2025, in Orlando, where the company will present multiple abstracts showcasing new data from its dermatology portfolio. The event will feature key findings on ruxolitinib cream (Opzelura®) for prurigo nodularis and axatilimab (Niktimvo™) for patients with dermatologic manifestations of chronic graft-versus-host disease (GVHD).
“We look forward to sharing new data for ruxolitinib cream (Opzelura®) across multiple indications, including prurigo nodularis, and axatilimab (Niktimvo™) in patients with dermatologic manifestations of chronic graft-versus-host disease (GVHD) at this year’s AAD Annual Meeting,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation and Autoimmunity, Incyte. “Incyte’s active participation in this key congress reinforces our commitment to addressing critical needs in dermatology while fostering meaningful dialogue with researchers, patients, and advocates to inform the development of innovative treatments.”
Key Abstracts to be Presented:
Late-Breaking Oral Presentation:
Prurigo Nodularis (PN):
- Efficacy and Safety of Ruxolitinib Cream in Patients With Prurigo Nodularis: Results From a Phase 3, Randomized, Vehicle-Controlled Study (TRuE-PN1)
Session: S028 – Late-Breaking Research: Session 1. Saturday, March 8, 2025, 9:24 a.m. ET
ePoster Exhibits:
Atopic Dermatitis (AD):
- Long-Term Safety of Ruxolitinib Cream in Adults and Adolescents with Mild-to-Moderate Atopic Dermatitis: Adverse Events of Interest from the TRuE-AD1 and TRuE-AD2 Phase 3 Studies
Abstract: #64524 - Association of Ruxolitinib Cream Initiation with Reduction in Use of Other Topical Treatments, Oral Corticosteroids, and Biologics for Atopic Dermatitis, Regardless of Previous Use of Biologics
Abstract: #64526 - 52-Week Disease Control and Safety with As-Needed Application of Ruxolitinib Cream in Children Aged 2 to 11 Years with Moderate and/or More Extensive Atopic Dermatitis: Subgroup Analysis from the TRuE-AD3 Study
Abstract: #64656 - Ruxolitinib Cream Demonstrated Long-Term Disease Control and Quality of Life Benefits in Adults and Adolescents with Mild to Moderate Atopic Dermatitis
Abstract: #64727
Graft-Versus-Host Disease (GVHD):
- Axatilimab for Patients with Dermatologic Manifestations of Chronic Graft-Versus-Host Disease: A Post Hoc Analysis
Abstract: #64616
Significance of These Findings:
Ruxolitinib cream (Opzelura®) has been a significant development in dermatology, particularly for inflammatory skin conditions such as atopic dermatitis and prurigo nodularis. Atopic dermatitis, a chronic skin condition affecting millions worldwide, is often associated with debilitating itching and inflammation. The TRuE-AD1 and TRuE-AD2 Phase 3 studies have provided critical long-term safety data that highlight ruxolitinib cream’s efficacy and its potential to reduce reliance on oral corticosteroids and biologic therapies.
The TRuE-PN1 study presents promising results for prurigo nodularis, a highly pruritic and chronic skin condition characterized by nodules that can severely impact the quality of life. The findings will likely shape future treatment protocols, offering hope for patients with limited treatment options.
For pediatric patients, the TRuE-AD3 study assesses the long-term safety and disease control of ruxolitinib cream in children as young as two years old. These insights are crucial for dermatologists seeking alternative therapies for young patients who require long-term management.
Axatilimab (Niktimvo™) represents another significant advancement in dermatology, particularly for patients with chronic GVHD. Chronic GVHD, a serious complication following hematopoietic stem cell transplantation, can cause extensive skin involvement. The post hoc analysis being presented at AAD 2025 will provide critical insights into the effectiveness of axatilimab in managing dermatologic symptoms of the disease.
Broader Implications for Dermatology:
Incyte’s presence at the 2025 AAD Annual Meeting underscores its growing role in dermatological innovation. By focusing on targeted therapies such as JAK inhibitors and novel biologics, the company continues to address significant unmet medical needs. The upcoming presentations not only reinforce the efficacy of Incyte’s dermatology portfolio but also foster collaborations among researchers and clinicians, ultimately leading to better patient outcomes.
The significance of these findings extends beyond clinical efficacy. The potential reduction in the need for systemic therapies like oral corticosteroids could mean fewer side effects and improved patient adherence to treatment regimens. In addition, the growing evidence supporting JAK inhibitors highlights their potential role in managing chronic inflammatory skin diseases.
Incyte’s Continued Commitment to Dermatology:
Incyte has demonstrated a sustained commitment to advancing dermatologic treatments through rigorous research and clinical trials. With Opzelura® already established as a leading treatment in the field, ongoing studies continue to expand its indications and refine its safety profile. The company is also actively engaged in investigating other potential dermatologic applications for its innovative therapies, ensuring continued progress in the field.
Incyte’s approach is rooted in collaboration with healthcare professionals, researchers, and patient advocacy groups to bring cutting-edge treatments to market. The company’s participation in AAD 2025 reflects its mission to enhance patient care by providing evidence-based solutions to complex dermatologic conditions.
